<SUBMISSION>
<ACCESSION-NUMBER>0001102624-08-000259
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20081014
<ITEMS>7.01
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20081014
<DATE-OF-FILING-DATE-CHANGE>20081014
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>THERAVANCE INC
<CIK>0001080014
<ASSIGNED-SIC>2834
<IRS-NUMBER>943265960
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-30319
<FILM-NUMBER>081121203
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>901 GATEWAY BLVD
<CITY>SOUTH SAN FRANCISCO
<STATE>CA
<ZIP>94080
<PHONE>6508086000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>901 GATEWAY BLVD
<CITY>S. SAN FRANCISCO
<STATE>CA
<ZIP>94080
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED MEDICINE INC
<DATE-CHANGED>20000302
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>theravance8k.htm
<DESCRIPTION>THERAVANCE, INC. 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: October   14, 2008</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>Theravance, Inc.</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>Delaware</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>000-30319</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>94-3265960</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>901 Gateway Boulevard, South San Francisco, CA</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>94080</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>650-808-6000</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 7.01. Regulation FD Disclosure</b></b><br>
<br>
The information in Items 7.01 and 9.01 (including Exhibit 99.1) of this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Items 7.01 and 9.01 (including Exhibit 99.1) of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
<br>
<br>On October 14, 2008, Theravance, Inc. issued a press release regarding its new drug application for telavancin, Theravance's bactericidal, once-daily injectable antibiotic proposed to treat complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.
<br>
<p>
<b>Item 8.01. Other Events</b></b><br>
<br>
On October 14, 2008, the Federal Register reflected that the new drug application for telavancin for the proposed treatment of cSSSI caused by Gram-positive bacteria, has been assigned a review by the U.S. Food and Drug Administration's Anti-Infective Drug Advisory Committee at 8:00 a.m. EST on November 19th, 2008.
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br>
<p>
<b>(d) Exhibits</b><br>
<br>

<p>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="theravanceinc8k4427.htm">Press Release of Theravance, Inc. dated October   14, 2008</a></b>
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table>
<tr>
<td width="50%" valign=top>
Dated: October   14, 2008<br>
</td>
<td>
<b>THERAVANCE, INC.</b>
<p>
By: <u>&nbsp;/s/ Rick E Winningham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Rick E Winningham<br>
&nbsp; &nbsp; &nbsp;<i>Chief Executive Officer</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of Theravance, Inc. dated October   14, 2008</td>
</tr>
</table>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>theravanceinc8k4427.htm
<DESCRIPTION>THERAVANCE, INC. PRESS RELEASE
<TEXT>

<p></p>
<b>Theravance Announces FDA Advisory Committee to Review Telavancin for the Treatment of Complicated Skin and Skin Structure Infections</b>
<p>SOUTH SAN FRANCISCO, CA -- 10/14/2008 --  Theravance, Inc. (NASDAQ: THRX) announced today that the Anti-Infective
Drugs Advisory Committee (AIDAC) to the U.S. Food and Drug Administration
(FDA) will convene to review the New Drug Application (NDA) for telavancin,
a novel, bactericidal, once-daily injectable investigational antibiotic,
for the proposed indication to treat complicated skin and skin structure
infections (cSSSI) caused by Gram-positive bacteria, including resistant
pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).  The
AIDAC meeting is scheduled for the morning of November 19, 2008 and will be
held at the Holiday Inn/College Park, College
Park, MD.
</p>
<p>
"We are pleased to have the Advisory Committee review our telavancin NDA,"
said Rick E Winningham, Chief Executive Officer of Theravance.  "The
Advisory Committee meeting signifies an important next step in the
telavancin NDA review process.  Based upon discussions with the FDA, we
believe the site inspection issues in the ATLAS program have been
successfully resolved.  The FDA requested that three clinical sites that
enrolled a total of 73 patients be removed from the ATLAS efficacy analysis
for Advisory Committee review.  The removal of this data had no impact on
the previously reported conclusions of the study.  We look forward to the
opportunity to present and discuss the clinical profile of telavancin."
</p>
<p>
About ATLAS 1 and ATLAS 2 Clinical Studies
</p>
<p>
The telavancin NDA is based on data from two large, multinational,
double-blind, randomized Phase 3 clinical studies designed to compare the
efficacy and safety of telavancin (10 mg/kg IV once daily) versus
vancomycin (1 gm IV q 12hr) in the treatment of cSSSI caused by
Gram-positive bacteria. In both of these studies (ATLAS 1 and ATLAS 2),
which enrolled and treated 1,867 patients in total, 719 of whom had
infections with MRSA, telavancin achieved its primary endpoint of
non-inferiority relative to the standard of care, vancomycin. The safety
profile of telavancin in these studies was compatible with treatment of
patients with serious infections.
</p>
<p>
About Theravance
</p>
<p>
Theravance is a biopharmaceutical company with a pipeline of internally
discovered product candidates. Theravance is focused on the discovery,
development and commercialization of small molecule medicines across a
number of therapeutic areas including respiratory disease, bacterial
infections and gastrointestinal motility dysfunction. The company's key
programs include:  telavancin for the treatment of serious Gram-positive
bacterial infections with Astellas Pharma Inc., the Horizon program and
Bifunctional Muscarinic Antagonist-Beta2 agonist (MABA) program with
GlaxoSmithKline plc, and the Gastrointestinal Motility Dysfunction program.
By leveraging its proprietary insight of multivalency toward drug discovery
focused primarily on validated targets, Theravance is pursuing a next
generation strategy designed to discover superior medicines in areas of
significant unmet medical need.  For more information, please visit the
company's web site at www.theravance.com.
</p>
<p>
About Telavancin Collaboration
</p>
<p>
In November 2005, Theravance entered into a collaboration arrangement with
Astellas Pharma Inc. for the development and commercialization of
telavancin worldwide except Japan. In July 2006, Theravance and Astellas
expanded the collaboration to include Japan. Under the terms of the
collaboration, Theravance will lead the development of and U.S. regulatory
activities for telavancin for the treatment of cSSSI (complicated skin and
skin structure infections), also known as cSSTI, and hospital-acquired
pneumonia, and will collaborate substantially with Astellas in marketing in
the United States for the first three years. Astellas will lead all other
development, regulatory, manufacturing, sales and marketing activities.
</p>
<p>
THERAVANCE&#174;, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE&#174;
are registered trademarks of Theravance, Inc.
</p>
<p>
This press release contains certain "forward-looking" statements as that
term is defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, statements relating to goals, plans,
objectives and future events. Theravance intends such forward-looking
statements to be covered by the safe harbor provisions for forward-looking
statements contained in Section 21E of the Exchange Act and the Private
Securities Litigation Reform Act of 1995. Examples of such statements
include statements regarding the potential benefits and mechanisms of
action of drug candidates, statements concerning the timing of seeking
regulatory approval of our product candidates (including with respect to
telavancin statements regarding any expectation that the third-party
manufacturer will successfully address the cGMP issues the FDA noted in the
approvable letter or that the FDA will approve the telavancin NDA on the
basis of existing preclinical and clinical data or at all), statements
regarding the enabling capabilities of Theravance's approach to drug
discovery and its proprietary insights and statements concerning
expectations for product candidates through development and
commercialization. These statements are based on the current estimates and
assumptions of the management of Theravance as of the date of this press
release and are subject to risks, uncertainties, changes in circumstances,
assumptions and other factors that may cause the actual results of
Theravance to be materially different from those reflected in its
forward-looking statements. Important factors that could cause actual
results to differ materially from those indicated by such forward-looking
statements include, among others, the potential that results of clinical or
preclinical studies indicate product candidates are unsafe or ineffective,
our dependence on third parties in the conduct of our clinical studies,
delays or failure to achieve regulatory approvals, risks of relying on
third-party manufacturers for the supply of our product candidates and
risks of collaborating with third parties to develop and commercialize
products. These and other risks are described in greater detail under the
heading "Risk Factors" contained in Item 1A of Theravance's Quarterly
Report on Form 10-Q filed with the Securities and Exchange Commission (SEC)
on August 7, 2008 and the risks discussed in our other periodic filings
with the SEC. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. Theravance assumes no
obligation to update its forward-looking statements.

</p>
<pre>
Contact Information:

Michael W. Aguiar
Senior Vice President and Chief Financial Officer
650-808-4100
investor.relations@theravance.com</a>


</pre>
</TEXT>
</DOCUMENT>
</SUBMISSION>
